Loading...
•
Mar 31, 2021
Biomea Fusion Q1 2021 Earnings Report
Reported financial results for the first quarter 2021.
Key Takeaways
Biomea Fusion reported a net loss attributable to common stockholders of $5.9 million for the first quarter of 2021, compared to a net loss of $0.4 million for the same period in 2020. As of March 31, 2021, the Company had cash, cash equivalents, restricted cash, and investments of $57.5 million.
Received $167 million in aggregate gross proceeds in April from initial public offering
Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021
Mick Hitchcock, Ph.D., former senior advisor to Gilead joined the Board of Directors
Completed initial public offering (“IPO”) in April. The Company’s common stock commenced trading on the Nasdaq Global Select Market under the ticker symbol “BMEA” on April 16, 2021.
Forward Guidance
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...